Design Therapeutics (DSGN) Operating Leases (2021 - 2026)

Design Therapeutics (DSGN) has 6 years of Operating Leases data on file, last reported at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 66.52% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (up 66.52% YoY), and the FY2025 full-year result was $645000.0, down 57.95% from the prior year.
• Operating Leases climbed to $2.2 million in Q1 2026, from $645000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $3.4 million in Q2 2022 to a low of $645000.0 in Q4 2025.
• A 5-year average of $2.2 million and a median of $2.2 million in 2026 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases plunged 57.95% in 2025 and surged 66.52% in 2026, its largest moves.
• Tracing DSGN's Operating Leases over 5 years: stood at $3.1 million in 2022, then declined by 23.5% to $2.3 million in 2023, then tumbled by 34.28% to $1.5 million in 2024, then sank by 57.95% to $645000.0 in 2025, then surged by 240.78% to $2.2 million in 2026.
• Business Quant data shows DSGN's Operating Leases at $2.2 million in Q1 2026, $645000.0 in Q4 2025, and $877000.0 in Q3 2025.